MRUS Sep 2024 50.000 call
| Previous close | 6.70 |
| Open | N/A |
| Bid | 9.00 |
| Ask | 10.80 |
| Strike | 50.00 |
| Expiry date | 2024-09-20 |
| Day's range | 6.70 - 6.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireMerus Announces Pricing of Upsized Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purch
Simply Wall St.These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat
The latest analyst coverage could presage a bad day for Merus N.V. ( NASDAQ:MRUS ), with the analysts making...
- GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET. The webcast of the presentation will be contemporaneous
